EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Traditional Chinese medicine monomers: a new strategy against diabetic kidney disease by regulating cholesterol efflux

Chenguang Wu, Jianing Sun, Junwei Shi, Zhe Li, Yan An, Han Zhu, Lifan Wang, Peng Liu

Frontiers in Nutrition · 25.11.2025 · 12

DOI: 10.3389/fnut.2025.1708809 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Nutrition, online erschienen am 25.11.2025. Verfasst von Chenguang Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Department of Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic kidney disease (DKD), a prevalent microvascular complication of diabetes, is driven by a complex pathogenesis. A key pathological hallmark of early DKD is intrarenal lipid deposition, a process pivotally driven by impaired cholesterol efflux. This efflux is critically mediated by ATP-binding cassette (ABC) transporters, primarily ABCA1 and ABCG1. Dysfunction of these transporters precipitates cholesterol accumulation in renal cells, subsequently inducing oxidative stress, inflammation, and fibrosis. Recently, a diverse range of herbal monomers has emerged as a promising class of therapeutic agents for DKD. Compounds—including Anthocyanins, Morroniside, Resveratrol, Tanshinone, Puerarin, Baicalin, Curcumin, Protocatechuic acid, and Kaempferol—have been shown to activate the PPARγ and LXRα signaling pathways. This activation upregulates the expression of ABCA1 and ABCG1, thereby enhancing cholesterol efflux, mitigating renal lipid deposition, and ultimately slowing DKD progression. However, this body of research is largely limited to preclinical studies in vitro and in animal models. Consequently, the complex, multi-target mechanisms of these compounds in vivo remain poorly understood. Future investigations should therefore leverage multi-omics technologies to comprehensively delineate these mechanisms. Furthermore, large-scale clinical trials are imperative to validate the therapeutic efficacy and safety of these agents, potentially establishing novel strategies for the prevention and treatment of DKD.

Schlagwörter

Stichwörter der Autor:innen

ABCA1PPARscholesterol effluxdiabetic kidney diseasetraditional Chinese medicine

Autor:innen und Institutionen

  • Renal Division, Department of Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China.
  • Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
  • Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.

Zitieren

APA

Wu, C., Sun, J., Shi, J., Li, Z., An, Y., Zhu, H., Wang, L., & Liu, P. (2025). Traditional Chinese medicine monomers: a new strategy against diabetic kidney disease by regulating cholesterol efflux. Frontiers in Nutrition, 12. https://doi.org/10.3389/fnut.2025.1708809

Vancouver

Wu C, Sun J, Shi J, Li Z, An Y, Zhu H, et al. Traditional Chinese medicine monomers: a new strategy against diabetic kidney disease by regulating cholesterol efflux. Frontiers in Nutrition. 2025;12. doi:10.3389/fnut.2025.1708809

BibTeX
@article{Wu2025,
  author = {Wu, Chenguang and Sun, Jianing and Shi, Junwei and Li, Zhe and An, Yan and Zhu, Han and Wang, Lifan and Liu, Peng},
  title = {Traditional Chinese medicine monomers: a new strategy against diabetic kidney disease by regulating cholesterol efflux},
  journal = {Frontiers in Nutrition},
  year = {2025},
  volume = {12},
  doi = {10.3389/fnut.2025.1708809}
}
Kostenlos starten →